


CLAIMS

1. A method for treatment of schizophrenia without being accompanied by any extrapyramidal symptoms, which comprises orally administering a daily dose of 5 mg to 120 mg of the active compound:
 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide of the formula (1):



or a pharmaceutically acceptable salt thereof to a patient suffering from schizophrenia once a day.

2. The method for treatment according to claim 1, wherein the active compound is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]-heptanedicarboximide hydrochloride.

3. The method for treatment according to claim 1 or claim 2, which improves the negative symptoms of schizophrenia.

4. The method for treatment according to claim 1 or claim 2, which improves the positive and negative symptoms of schizophrenia.

5. The method for treatment according to claim 1 or claim 2, which comprises orally administering the active compound: (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride at a daily dose of 20 mg to 80 mg once a day.

6. The method according to claim 5, which improves the negative symptoms of schizophrenia.

7. The method according to claim 5, which improves the positive and negative symptoms of schizophrenia.

8. The method for treatment of schizophrenia in the chronic stage according to claim 1 or claim 2, which improves schizophrenia without being accompanied by any extrapyramidal symptoms by orally administering the active compound: (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo [2.2.1]heptanedicarboximide hydrochloride at a daily dose of 5 mg to 80 mg once a day.

9. The method for treatment according to claim 8, which improves the negative symptoms of schizophrenia.


10. The method for treatment according to claim 8, which improves the positive and negative symptoms of schizophrenia.

11. The method for treatment according to claim 8, which comprises orally administering the active compound: (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride at a daily dose of 10 mg to 40 mg once a day.

12. The method for treatment according to claim 11, which improves the negative symptoms of schizophrenia.

13. The method for treatment according to claim 11, which improves the positive and negative symptoms of schizophrenia.

14. An agent for treatment of schizophrenia, which comprises as an active compound (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo [2.2.1]heptanedicarboximide of the formula (1):




or a pharmaceutically acceptable salt thereof in an amount of 5 mg to 120 mg as a daily dose for oral administration once a day.

15. The agent according to claim 14, wherein the active compound is
 5 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo [2.2.1]heptane-dicarboximide hydrochloride.

16. The agent according to claim 14 or claim 15, wherein the content of the active compound is in the range of 20 mg to 80 mg.

10 17. A use of (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo [2.2.1]heptane-dicarboximide of the formula (1):



or a pharmaceutically acceptable salt thereof in the preparation of an
 15 agent for treatment of schizophrenia.

18. The use according to claim 17, wherein the active compound is
 (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl-
 methyl]-1-cyclohexylmethyl]-2,3-bicyclo [2.2.1]heptanedicarboximide
 hydrochloride.

20 19. The use according to claim 17 or claim 18, wherein the agent for treatment of schizophrenia contains the active compound in an amount of 5 mg to 120 mg as a daily dose for oral administration once a day.